Invivyd, Inc. (NASDAQ:IVVD) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers grew its holdings in shares of Invivyd, Inc. (NASDAQ:IVVD) by 4,434.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,017 shares of the company’s stock after buying an additional 82,164 shares during the quarter. Rhumbline Advisers owned 0.07% of Invivyd worth $92,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in IVVD. SG Americas Securities LLC purchased a new position in Invivyd in the first quarter valued at about $56,000. Tidal Investments LLC bought a new position in Invivyd during the first quarter worth $126,000. Chase Investment Counsel Corp bought a new position in Invivyd during the first quarter worth $271,000. Acadian Asset Management LLC acquired a new position in Invivyd in the first quarter worth $905,000. Finally, Bank of New York Mellon Corp bought a new stake in Invivyd during the second quarter valued at $263,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.02 on Tuesday. The firm has a market capitalization of $121.70 million, a PE ratio of -0.55 and a beta of 0.61. The stock has a fifty day moving average of $1.05 and a two-hundred day moving average of $1.79. Invivyd, Inc. has a 1 year low of $0.81 and a 1 year high of $5.20.

Invivyd (NASDAQ:IVVD) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.91 million. Equities research analysts predict that Invivyd, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Invivyd in a research report on Tuesday, September 3rd.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.